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Transmission-blocking interventions eliminate
malaria from laboratory populations
A.M. Blagborough1, T.S. Churcher2, L.M. Upton1, A.C. Ghani2, P.W. Gething3 & R.E. Sinden1,4
Transmission-blocking interventions aim to reduce the prevalence of infection in endemic
communities by targeting Plasmodium within the insect host. Although many studies have
reported the successful reduction of infection in the mosquito vector, direct evidence that
there is an onward reduction in infection in the vertebrate host is lacking. Here we report the
ﬁrst experiments using a population, transmission-based study of Plasmodium berghei in
Anopheles stephensi to assess the impact of a transmission-blocking drug upon both insect and
host populations over multiple transmission cycles. We demonstrate that the selected
transmission-blocking intervention, which inhibits transmission from vertebrate to insect by
only 32%, reduces the basic reproduction number of the parasite by 20%, and in our model
system can eliminate Plasmodium from mosquito and mouse populations at low transmission
intensities. These ﬁndings clearly demonstrate that use of transmission-blocking interven-
tions alone can eliminate Plasmodium from a vertebrate population, and have signiﬁcant
implications for the future design and implementation of transmission-blocking interventions
within the ﬁeld.
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M
alaria is a global disease of man caused by parasites of
the genus Plasmodium, which are transmitted exclu-
sively by Anopheles mosquitoes. There are an estimated
219 million human malaria cases annually—90% of resulting
deaths occur in Africa, with children under the age of 5 and
pregnant women most severely affected1. If we are to contemplate
control or elimination of malaria, it is now recognized that we
must attack Plasmodium directly on two fronts; we must reduce
the impact of disease upon the infected individual, and at the
population level we must reduce the number of new infections.
Current analyses suggest that to reduce new infections, potentially
the most effective point to attack the parasite is during its
transmission through the mosquito vector2, a process that in the
ﬁeld, commonly results in infection of o5 parasites per
mosquito3,4. Targeting Plasmodium within the vector (using
either transmission-blocking drugs or vaccines) aims to reduce
both the prevalence of infected mosquitoes and the parasite
burden in individual infected insects, consequently reducing the
exposure of a human population to potentially infectious
mosquitoes. Successful use of an anti-malarial transmission-
blocking intervention (TBI) should, as its overall objective, aim to
reduce the number of secondary malarial infections. This
important parameter has never been experimentally investigated.
Malaria endemicity is typically measured using the entomolo-
gical inoculation rate (EIR). It is calculated by multiplying the
host biting rate (the average number of bites per person per unit
time) by the sporozoite rate (the proportion of biting mosquitoes
which contain salivary gland sporozoites). Mathematical model-
ling studies have indicated that TBIs could be most effective in
areas of low transmission with low EIRs5,6. Other studies have
questioned whether usage of TBIs could reduce malaria infection
and malaria-related morbidity and mortality across all
transmission settings7. To our knowledge, laboratory-based
evidence to support these in silico predictions does not exist.
Given the current international interest in interrupting malaria
transmission, a wide range of novel TBIs have been investigated
using a variety of assays designed to measure efﬁcacy. These
assays (for example, the standard membrane feeding assay
(SMFA) and direct feeding assay (DFA)), typically measure
parasite development within the mosquito, assessing efﬁcacy as
reduction in parasite prevalence or intensity8,9. Although
undeniably informative, such assays have highly variable (and
density-dependent) readouts10. Moreover, the assay end points
do not measure reduction in the number of secondary malarial
infections, thus preventing the determination of transmission
reductions required to have a signiﬁcant impact in different
endemic situations. Future regulatory approval for TBIs may
require laboratory data demonstrating the effectiveness of these
interventions: currently, no such data have been published.
Current go/no-go efﬁcacy thresholds for an effective transmis-
sion-blocking vaccine have been suggested to be an 80%
reduction in oocyst intensity in the mosquito midgut11,12.
However, we have no practical evidence whether, and under
what ﬁeld conditions (for example, transmission intensities/EIR),
such levels of inhibition could effectively reduce transmission.
Here we report a transmission-based population ‘bottle’ study
to assess how a TBI will reduce the number of secondary cases of
malarial infection if applied over multiple transmission cycles
within closed populations of insect and vertebrate hosts. We have
used the rodent malaria parasite P. berghei, the only mammalian
system in which these experiments are at present both technically
and ethically possible. The impact of a TBI is investigated at ﬁve
different transmission intensities, which are generated by altering
the number of (potentially) infectious mosquitoes that bite
individual naive mice (that is, one, two, three, four or ﬁve bites
per mouse)—which we term the mosquito biting rate (MBR).
Using a previously characterized TBI, atovaquone (ATV)13, we
have shown that a TBI that only partially reduces oocyst intensity
and prevalence can, in the absence of any other intervention,
eliminate Plasmodium infection from both mosquito and mouse
populations within three cycles of transmission at low MBRs. At
higher MBRs, the parasite is not eliminated from either
population. This is the ﬁrst practical demonstration that
successive rounds of anti-parasite transmission blockade have
the potential to eliminate malarial infection in a mammalian
population. We extend the impact of our ﬁndings to inform the
potential applications of TBI usage on a global scale, and suggest
that a signiﬁcant fraction of malaria affected communities could
beneﬁt from the application of TBIs of a similar or higher efﬁcacy.
Results
Assessment of intervention efﬁcacy by DFA. To establish the
effect of transmission blockade on parasite dynamics over suc-
cessive rounds of transmission, we used the proven and highly
reproducible transmission-blocking drug ATV. ATV is a broad
range 8-aminoquinoline anti-malarial, with well-established
activity against transmission stages13. Transmission-blocking
(TB) efﬁcacy, as classically deﬁned at the chosen dose
(0.5 mg kg 1, intraperitoneal (i.p.)), was determined using the
standard DFA14 (Fig. 1). The drug achieved a mean 57.3%
reduction in oocyst intensity (95% conﬁdence interval (CI) 38.9–
70.2%) and a 32.3% reduction in infection prevalence (95% CI
11.1%–47.6%) (hear after referred to as an efﬁcacy of TBooc 57/
32%). Negative controls received dimethyl sulfoxide (DMSO)
(i.p.).
Experimental design of transmission-based population model.
Five successive rounds of mouse–mosquito–mouse transmission
were performed (Fig. 2, Supplementary Data S1). Five paired
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Figure 1 | Transmission-blocking impact of atovaquone on P. berghei as
determined by direct-feed assay. ATV dosage used was 0.5 mg kg 1.
An equal volume of DMSO (i.p.) was used as a negative control. Oocysts
present on the mosquito midguts were counted 10 days post feeding. Each
data point represents a single mosquito within an individual treatment
group. X-axis points represent individual mice. Blue horizontal line indicates
the mean number of oocysts for the negative control treatment; red
horizontal line indicates the mean number of oocysts for all three ATV
replicates. Mean ATV impact from three replicates was 57.3% reduction in
oocyst intensity and a 32.3% reduction in infection prevalence (hereafter
referred to as TBooc 57/32%).
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experiments were conducted in parallel, at ﬁve different MBRs.
Individual naive mice were exposed to given numbers (1–5) of
potentially infectious mosquitoes taken at random from a larger
population of Anopheles stephensi. Within individual paired
experiments, one population was exposed to the TBI and one was
maintained without TBI treatment. To ensure comparability of
data, all populations were seeded from the same mosquito and
parasite populations. For every cycle, parasite transmission was
monitored by measuring the following outputs: parasitemia/
gametocytemia in mice from the initial population, oocyst
intensity/prevalence (and related TB impact), proportion of biting
mosquitoes with salivary gland sporozoites and prevalence of
blood-stage infection in subsequent mouse populations.
Effect of intervention on transmission at different biting rates.
In these studies, we have expressed the impact of the TBI on
successive rounds of transmission as the effect on the parasite
within the mosquito vector (assessed as infection prevalence and
intensity), or within the vertebrate host (assessed as prevalence of
blood-stage infection at day 10 post bite) (Fig. 3).
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Figure 2 | Experimental design of population transmission experiments. (a) A single experimental round of mouse–mosquito–mouse transmission using
P. berghei and Anopheles stephensi. (b) Schematic of performed population transmission experiments. Total number of mosquitoes and mice used are
described. Ten paired parallel transmission experiments were performed, for ﬁve successive cycles of transmission. Red arrows indicate transmission
carried out in presence of TBI (TBooc 57/32%), blue arrows indicate transmission carried out in absence of TBI (with control). Five MBRs of one to ﬁve
(potentially infected mosquito bites per naive mouse) were examined.
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In the absence of TBI, at any chosen MBR, parasite trans-
mission is broadly stable across ﬁve successive cycles, with no
signiﬁcant change in oocyst intensity/prevalence in the mosquito
population, or prevalence of blood-stage infection in the verte-
brate population. As expected, increasing the MBR increased the
proportion of mice infected. Following administration of the TBI,
at lower MBRs (one and two bites), Plasmodium was progres-
sively reduced in terms of oocyst intensity and prevalence (in the
mosquito population), as was blood-stage parasitemia (in the
vertebrate population). The parasite was subsequently eliminated.
At an MBR of 1, the parasite is eliminated from the mosquito
population by cycle 2, and from the mouse population by cycle 3.
At an MBR of 2, elimination from both mosquito and mouse
population occurs by cycle 3. At MBRs of 3 or higher, the parasite
is not eliminated from the mosquito population and there is no
signiﬁcant reduction observed in the prevalence of blood-stage
infection within the vertebrate hosts.
The overall effectiveness of an intervention can be quantiﬁed
by estimating its ability to reduce the basic reproduction number
(that is, R0), the average number of secondary cases of malaria
resulting from a single case in an otherwise uninfected
population. Correspondingly, the term RC is often used to
describe the basic reproduction number under control interven-
tions. If RC is sustainably reduced too1, malarial transmission is
considered non-sustainable. The magnitude of the reduction in
R0 or RC has been termed the ‘effect size’15 and measures the
ability of an intervention to reduce the probability of transmission
from human-to-vector and vector-to-human. If it is assumed
that that all infectious mosquitoes are equally infectious then
the effect size can be estimated by ﬁtting a chain binomial model
to the data16. Overall, our experiment indicates that use of our
TBI (with TBooc 57/32%) over successive transmission cycles
results in an effect size of 20.4% (95% CI 15.2–24.9%). Further
data concerning oocyst intensity, oocyst prevalence and
proportion of biting mosquitoes with salivary gland sporozoites
over successive rounds of transmission are provided in
Supplementary Table S1.
To preclude the possibility of drug resistance having emerged
at the higher transmission intensities after repeated rounds of
ATV treatment, at the end of ﬁve transmission cycles, surviving
parasites (from experiments conducted at transmission intensities
Z3) that had been exposed to drug were tested for ATV
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Figure 3 | Effect of a TBI with an efﬁcacy of TBooc 57/32% on host/vector infection over successive rounds of transmission. Each row shows a different
MBR with mice receiving either one, two, three, four or ﬁve bites per generation. The ﬁrst column (blue bars) shows the number of mice developing
parasitemias over the different rounds of the experiment, the second column (green bars) the percentage of mosquitoes developing oocysts and third
column (red bars) the mean intensity of oocyst per mosquito. Lighter bars denote control group with no intervention while darker bars signify those
administered with the TBI. Vertical grey lines indicate 95% CIs. Red stars indicate the number of rounds required for there to be a statistically signiﬁcant
difference between the control and treatment arms of the experiment (*Po0.05, **Po0.001). At each generation at a single biting rate, for mice n¼ 10,
mosquitoes n¼ 1,000.
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resistance. All parasites demonstrated ATV sensitivity identical to
the originating wild-type parasite (Supplementary Fig. S2).
Discussion
Anti-malarial TBIs aim to interrupt the development of the
parasite through the mosquito host, and therefore reduce the
number of secondary malarial infections within a human
population. The potential effectiveness of any TBI under ﬁeld
conditions will depend on a number of highly variable factors,
including endemic transmission/EIR levels, TBI efﬁcacy, TBI
coverage levels, the distribution of the number of oocysts per
mosquito and the proportion of biting mosquitoes that carry
sporozoites12.
Currently, assays to determine TBI effectiveness do not
measure the reduction in the number of secondary malarial
infections, but typically measure intermediate parasite outputs
within the insect vector8,10,17. As a result, there are no primary
data to link the required TBI efﬁcacy to reduction in secondary
infection within the coindigenous human population. We report
the ﬁrst proof of concept studies to link these two end points, and
further demonstrate the critical importance of understanding
their dependence upon transmission intensity. This study further
outlines the importance of multigenerational transmission studies
when assessing the impact of a TBI.
Traditionally, TBI impact is measured within one transmission
step (host-to-vector). Current TBI development pipelines suggest
that an 80% reduction in oocyst intensity11,12 should be a
threshold efﬁcacy for future development. We show that both of
these conventions fail to appreciate that a TBI of incomplete
efﬁcacy (here TBooc 57/32%) can eliminate Plasmodium from
both mosquito and vertebrate populations at low transmission
levels over successive rounds of application. This has obvious
implications for the future design and usage of TBIs in highly
variable endemic situations. We are not suggesting using ATV as
part of a malaria control programme, or utilizing a TBI of this
efﬁcacy in the ﬁeld; however, we can certainly expect that the
(modest) efﬁcacy examined here will be exceeded by that of TBIs
currently under development, for example, SMFA data using
anti-Pfs25 antibodies have resulted in up to a 96% reduction in
oocyst intensity18–20, and anti-Pfs48/45 and Pfs230 antibodies
have reported up to 90% and 100% reductions in intensity,
respectively21–23. Lead candidates for development as
transmission-blocking drugs also demonstrate signiﬁcantly
higher potency, for example, the spiroindolone drug NITD609
has demonstrated a dose-dependent effect on P. falciparum
oocyst counts in the SMFA, with a TBooc of 100/100% observed at
500 nM (ref. 24).
This study provides clear evidence that the ability of a TBI to
eliminate malaria will depend on the transmission intensity.
Transmission was halted in populations where each mouse
received one or two bites and was maintained in those receiving
three, four or ﬁve bites. A signiﬁcant reduction in mosquito
infection (both oocyst prevalence and intensity) was observed in
the group which received three bites with application of TBI. This
may subsequently result in fewer vertebrate infections, although
as only ﬁve mice were used in each population it was not possible
to show a statistically signiﬁcant reduction at this MBR.
Previously, theoretical studies to examine malarial transmis-
sion have predicted that TBIs could impact the number of
malarial cases within the ﬁeld under a variety of conditions,
particularly at levels of low transmission5,6. Other studies have
additionally suggested that use of a TBI at relatively low effective
coverages could give a substantial reduction in the number of
malarial cases25. Our simple lab-based, multi-cycle population
model supports both of these conclusions, indicating that usage
of a TBI with a modest efﬁcacy will achieve elimination of
Plasmodium berghei within the laboratory at levels of
transmission where MBR r2. Further application of these
experiments must examine the required efﬁcacies and coverages
for TBIs to eliminate Plasmodium at higher host biting rates, such
that we will be able to provide experimental justiﬁcation of the
TBooc efﬁcacy required for TBIs to achieve elimination in
different transmission settings.
We are acutely aware that the transmission intensities
described within this study may not be directly translatable to
transmission as measured in natural populations of human
malaria. Experimental studies have determined that vertebrate–
mosquito–vertebrate transmission is much more efﬁcient in our
laboratory model than in naturally found parasite–vector
combinations4,9. Nevertheless, if a TBI candidate had an effect
size in humans of 20.4%, as was seen here within our rodent
model system, then epidemiological theory indicates that if it was
given and maintained in 100% of the population it would result in
malarial elimination in areas where the Rc was o1.255. Recent
disease maps26 illustrate that 74.77% of the malaria affected
population and 63.14% of malaria affected areas are located in
areas where an Rco1.255 (Fig. 4). These combined data suggest
that widespread use of a TB vaccine or drug with a higher efﬁcacy
(for example, those examined in refs 17–23) could have
signiﬁcant and widespread implications for global health and
malarial burden.
The wide range of new TBIs (both drugs and vaccines)
currently under development will require Phase 3, likely to be
placebo controlled, randomized trials where the unit of
randomization will be a village and the outcome will be the
RC>1.255
RC<1.255
Unstable
Risk free
Figure 4 | Spatial global malaria distribution of areas with Rco1.255. Blue: Rc41.255, yellow: Rco1.255. Areas of unstable transmission (medium grey
areas) or no risk (light grey) are also indicated.
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reduction in transmission as measured by decreased incidence of
infection12. Recognizing the high ﬁnancial cost of these studies, it
is important to develop realistic go/no-go criteria for efﬁcacy
before progressing TBI development to this level. The studies
described here may offer a robust, accurate, safe and cost-effective
manner to experimentally examine these critical parameters. The
strength of the experimental design we have developed is that our
protocol provides a technically accessible and ethical framework
to examine, over multiple cycles of transmission, the population
dynamics of transmission blockade in a host population, with
direct control of individual regulating parameters (for example,
TBI efﬁcacy) which in the ﬁeld may be simultaneously
uncontrollable, variable and often unmeasurable.
Our data and subsequent analyses strongly support the notion
expressed in numerous other studies5,12,27,28 that malaria control
presents variable challenges across its transmission spectrum, and
that strategic planning for control or elimination should consider
a number of factors, with particular emphasis on the efﬁcacy of
TBI required, and the transmission intensity/EIR in the targeted
area. The design and ﬁeld implementation of an anti-malarial TBI
is likely to be both complex and multifaceted, although our data
suggest that we may be closer than we previously thought to the
utilization of an effective anti-malarial TBI.
Methods
DFA to establish ATV efﬁcacy. Six days before mosquito feed, 4- to 10-week-old
female TO mice were treated i.p. with 200 ml phenylhydrazine (6mgml 1 in PBS;
ProLabo, UK). Three days before feeding, mice were infected i.p. with 107–108
parasitized red blood cells, infected with P. berghei ANKA 2.34. One day before
feeding, mosquitoes were placed in an appropriate container and starved for 24 h.
For each mouse,B60 female A. stephensi (SD 500) mosquitoes were potted. On the
day of the mosquito feed, parasitemia, gametocytemia and presence of exﬂagella-
tion were recorded as described previously14. Mice were injected i.p. with ATV
(Sigma Aldrich, no. A7968) dissolved in DMSO to give a ﬁnal dose of 0.5 mg kg 1
in 100ml volume. Hundred microlitres DMSO alone (i.p.) was used as negative
control. Post treatment, mice were left for 2 h, after which, mice were anesthetized
and pots of starved A. stephensi mosquitoes were allowed to feed on each infected
mouse. Twenty four hours after feeding, mosquitoes were brieﬂy anesthetized with
CO2, and unfed mosquitoes were removed. Mosquitoes were maintained on 8% (w/
v) fructose, 0.05% (w/v) p-aminobenzoic acid at 19 C and 80% relative humidity.
At day 10 post feeding, 50 mosquito midguts were dissected, and oocyst prevalence
and intensity recorded. For inhibition calculations these values were compared
with mean oocyst intensity and infection prevalence in control (DMSO) groups. All
care and handling of animals was in accordance with the Guidelines for Animal
Care and Use prepared by Imperial College London. The efﬁcacy of the
intervention was calculated (over all replicate experiments) using a generalized
linear mixed effects model10. Treatment was included as the ﬁxed effect while
efﬁcacy between replicates was allowed to vary at random between replicates. A
binomial error structure was used for the parasite presence/absence data while a
zero-inﬂated negative binomial distribution was used to describe mosquito oocyst
intensity. Efﬁcacy 95% CI estimates were generated by bootstrapping methodology
(with 100,000 replicates).
Successive rounds of P. berghei transmission. Five successive rounds of mouse–
mosquito–mouse transmission were performed, with general parasite maintenance
carried out as described12. Brieﬂy, for each individual transmission setting under
investigation, two groups of ﬁve P. berghei ANKA 2.34 parasites were maintained
in 4- to 10-week-old female TO mice by syringe inoculation (i.p.), followed by
mouse–mosquito–mouse passage. For each transmission cycle infections were
monitored on Giemsa-stained tail blood smears as described14. At day 10 post
infection, individual groups of mice were treated with either ATV at a ﬁnal dose of
0.5 mg kg 1 in 100ml volume (i.p.), or 100 ml DMSO alone (i.p.) as negative control.
Post treatment, mice were left for 2 h, after which, groups of ﬁve mice were
anesthetized and exposed to cages containing 500 starved female A. stephensi (SD
500) mosquitoes. Unfeds were removed and mosquitoes were maintained as
described above. On day 10 post feeding, from a 50-mosquito sample taken from
each individual cage, midguts were dissected, and oocyst prevalence and intensity
recorded. For each mosquito population, oocyst numbers were counted and mean
oocyst intensity was calculated. To calculate inhibition, this number was compared
with the relevant control group. Remaining mosquitoes were maintained until 21
days post infection, when salivary gland sporozoites were at their peak14. Individual
transmission intensities were established by exposing individual, anesthetized naive
mice to set numbers (between 1 and 5) of potentially infectious mosquitoes,
selected at random from the larger population. Successful feeding was conﬁrmed by
the presence of blood in the abdomen of mosquitoes after 20min. Post feeding,
individual mosquitoes were dissected to determine the percentage with salivary
gland sporozoites, and salivary gland sporozoites scored on a log scale (score of
0¼ no sporozoites visible; 1¼ 1–10 sporozoites visible; 2¼ 10–100 sporozoites
visible; 3¼ 100–1,000 sporozoites visible; 4¼ 1,000þ sporozoites visible). Post
feeding, mice were maintained for 10 days. From days 6 to 10, naive mice were
smeared daily as described in ref 14. At day 10 post infection, P. berghei
gametocytes present in infected mice are at their optimal infectivity to
mosquitoes29. At this time, groups of mice were treated with either ATV at a ﬁnal
dose of 0.5 mg kg 1 (i.p.), or DMSO alone (i.p.). Post treatment, mice were left for
2 h, after which, groups of ﬁve mice were anesthetized and exposed to new cages
containing 500 naive starved female A. stephensi (SD 500) mosquitoes, completing
a cycle of mouse–mosquito–mouse transmission. For each individual experiment,
ﬁve successive rounds of transmission were performed. 10 individual experiments
were performed in parallel, at ﬁve different levels of transmission intensity (1, 2, 3,
4 and 5 mosquitoes exposed to naive mice). Five experiments were performed with
ATV (0.5 mg kg 1), and ﬁve paired populations with DMSO alone.
After ﬁve rounds of cyclic transmission, from each experiment, P. berghei-
infected blood was collected by cardiac puncture, and tested for persisting
sensitivity to ATV by DFA as described above. Results demonstrating continued
drug sensitivity are shown in Supplementary Fig. S2.
Data regarding proportion of biting mosquitoes with salivary gland sporozoites,
oocyst intensity and oocyst prevalence from all experiments over ﬁve successive
rounds of transmission are included in Supplementary Data. Data regarding the
proportion of biting mosquitoes with salivary gland sporozoites over successive
rounds of transmission is provided in Supplementary Table S1, and data regarding
continued sensitivity of P. berghei after ﬁve cycles of transmission is provided in
Supplementary Fig. S2.
Statistical analysis of cyclic transmission. Generalized linear models were used
to determine whether administering a TBI signiﬁcantly inﬂuenced mouse and
mosquito infectivity over the different rounds of infection for a population with a
speciﬁc biting rate. For each biting rate, the model determined the number of
rounds of the life cycle required before including information on whether the
mosquito/mouse was in the control or intervention arm signiﬁcantly improves the
ﬁt of the model (using a likelihood ratio test). A binomial error structure was used
for the parasite presence/absence data while a zero-inﬂated negative binomial
distribution was used to describe mosquito oocyst intensity. Ninety-ﬁve per cent
CIs were generated using bootstrapping methodologies (with 100,000 replicates).
Calculation of effect size of intervention. Let pi denote the prevalence of
infection in mice and qi the prevalence in mosquitoes at generation i (when
i¼ 0..5). Generation 0 is initiated in mice with p0¼ 1. Let r denote the (per bite)
probability of infection from an infected mosquito to a susceptible mouse, s the
probability of infection from an infected mouse to a susceptible mosquito and m
the MBR. Assuming that the probability that a mosquito transmits the infection is
the same, irrespective of the number of bites the mouse receives, then the
probability that a susceptible mouse is infected after exposure to m mosquito bites
in generation i is described in equation (1):
fim ¼ 1ð1 rqi 1Þm: ð1Þ
The probability that a mosquito is infected at generation i (denoted simcwhere c
is signiﬁes the treatment arm) in the control group (that is, c¼ 0) is described in
equation (2):
sim0 ¼ spi: ð2Þ
Assuming that the ATV acts to reduce the probability of transmission from
mouse to mosquito, in the intervention group this probability is described in
equation (3):
sim1 ¼ð1 vÞspi ð3Þ
where v is the effect size. This model is show diagrammatically in Supplementary
Fig. S1. A chain binomial model can then be constructed to calculate, given
estimates of the three parameters r, s and v, the expected prevalence of infection
in mice and mosquitoes at each generation is described in equation (4):
p0 ¼ 1;
q0 ¼ p0s0mc¼ s0mc
p1 ¼ q0f1m ¼f1ms0mc
q1 ¼ p1s1mc¼f1ms1mcs0mc;
and so on
ð4Þ
Or more generally:
pi ¼
Y
j¼ 1::i
k¼ 0::i 1
fjmskmc; qi ¼
Y
j¼ 1::i
k¼ 0::i
fjmskmc:
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Maximum likelihood estimation. Let xi be the observed number of infected mice
in generation i and ni the number of mice that were bitten. Similarly let yi be the
observed number of infected mosquitoes in generation i and zi the number of
mosquitoes that were fed. Using the notation x to denote the corresponding list of
observations, under a binomial model, the data likelihood is proportional to
equation (5):
Lðx; n; y; z r; s; vj Þ /
Y
m;c
sy00mcð1 s0mcÞz0  y0
Y
i¼ 1::5
fxiimð1fimÞni  xisyiimcð1simcÞzi  yi : ð5Þ
This likelihood can be maximized to obtain estimates of r, s and v from the
experimental data. Conﬁdence intervals for the parameters were obtained from the
proﬁle likelihood.
Spatial distribution of malaria transmission intensity. The basic reproduction
number for malaria, PfR0, quantiﬁes the potential for the disease to spread within a
naive population30,31. The same metric for scenarios moderated by malaria control
has been termed PfRc (ref. 5). A full description of the data and methods used to
generate a contemporary global map of estimated PfRc for the year 2010 has been
reported previously26. In brief, routine case reporting data (annual parasite
incidence) for 13,449 administrative units in 43 endemic countries were sourced to
deﬁne the spatial limits of P. falciparum transmission in 2010. A total of 22,212
P. falciparum parasite rate (PfPR) surveys were then used in a model-based
geostatistical (MBG) prediction to create a continuous contemporary surface of
malaria endemicity (the P. falciparum parasite rate, age-standardized to the 2–10
year age range, PfPR2–10) within these limits. A malaria transmission model was
then utilized to describe the relationship between PfPR and PfRc. The model
assumed that infections by different parasite types can accumulate in a single
human host (super infection), and that they clear independently. The model also
assumed that exposure risk is distributed unevenly in the population
(heterogeneous biting) but is well-characterized and described by a one-parameter
family of g distributions. The model ignores acquired immunity and its effects, and
the steady-state assumption implies that a population has been exposed for some
time, so it is most suitable for describing malaria prevalence in older children, that
is, for PfPR2–10. This model was then used to convert the predicted values of
PfPR2–10 at each pixel into equivalent predictions of PfRc. In the present study,
the resulting map was classiﬁed according to our target threshold of PfRc values
above or below 1.255.
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